Yasutoshi Kuboki

23PUBLICATIONS
186CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|May 01, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

|Apr 16, 2026
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings.

|Mar 30, 2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer.

John H Strickler, Judith Raimbourg, Jonathan E Cohen

|Mar 13, 2026
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.

Yonina R Murciano-Goroff, Antoine Hollebecque, Rebecca S Heist

|Feb 17, 2026
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.

Ben Tran, Mark Voskoboynik, Sang-We Kim

|Jan 22, 2026
Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.

Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki

Pageof 4

Frequent Collaborators

4 joint publications

Takayuki Yoshino

4 joint publications

Toshihiko Doi

3 joint publications

Enriqueta Felip

3 joint publications

Hideaki Bando